Table 1.

Patient characteristics

CharacteristicNewly diagnosedRelapsedLong-term remission
Total no. of patients 41 9 43
Sex, F/M 14/27 5/4 17/26
Mean age at diagnosis, y 31 41 30
Clinical stage IIB/III/IV, no. (%) 20 (49) 5 (66) Not applicable
Prognostic score 3 or more*, no. (%) 12 (29) 4 (44) Not applicable
Timing of blood sample(s) Prior to therapy, 6 mo, 12 mo Prior to therapy, 6 mo, 12 mo Mean, 5 y; range, 2-33 y after diagnosis
Histology, no. of total (%)
    Nodular sclerosing 27/41 (66) 7/9 (78) 18/36 (50)
    Mixed cellularity 7/41 (17) 1/9 (11) 6/36 (17)
    Lymphocyte rich 4/41 (10) 0/9 (0) 4/36 (11)
    Lymphocyte depleted 1/41 (2) 0/9 (0) 1/36 (3)
    Nodular lymphocyte predominant 2/41 (5) 1/9 (11) 3/36 (8)
    Unclassified Hodgkin 0/41 (0) 0/9 (0) 4/36 (11)
Positive EBV serology, no. of total (%) 39/40 (98) 8/9 (89) 40/43 (93)
Positive EBV tissue status§, no. of total (%) 15/41 (36) 1/9 (11) 9/27 (33)
  • * Hasenclever/Diehl International Prognostic Score.

  • Histology available in all newly diagnosed and relapsed cases and 36 of 43 (84%) remission cases.

  • Serology undetermined in 1 newly diagnosed case.

  • § Biopsy available for EBV testing in all newly diagnosed and relapsed cases and 27 of 43 (63%) remission cases. EBV tissue status correlated with histology, with 55% of mixed cellularity or lymphocyte-rich cases positive for EBV, against 27% of nodular sclerosing cases (r = 0.38, P = .013). In 2 of 67 cases the LMP1 and EBER stains were discordant (EBER positive/LMP1 negative). Both cases were classified as EBV tissue positive.